Thus, restoring NEIL2 levels could improve therapy for severe exacerbations, slow the progression of COPD in subjects at risk for a more rapid decline in lung function and/or frequent exacerbations and reduce the risk of malignancy in certain subgroups. This evidence concerns the gene NEIL2 and chronic obstructive pulmonary disease.